Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Zhu C, Kalincik T, Horakova D, Zhou Z, Buzzard K, Skibina O, Alroughani R, Izquierdo G, Eichau S, Kuhle J, Patti F, Grand'Maison F, Hodgkinson S, Grammond P, Lechner-Scott J, Butler E, Prat A, Girard M, Duquette P, Macdonell RAL, Weinstock-Guttman B, Ozakbas S, Slee M, Sa MJ, Van Pesch V, Barnett M, Van Wijmeersch B, Gerlach O, Prevost J, Terzi M, Boz C, Laureys G, Van Hijfte L, Kermode AG, Garber J, Yamout B, Khoury SJ, Merlo D, Monif M, Jokubaitis V, van der Walt A, Butzkueven H; MSBase Study Group. Zhu C, et al. Among authors: yamout b. JAMA Neurol. 2023 Jul 1;80(7):739-748. doi: 10.1001/jamaneurol.2023.1542. JAMA Neurol. 2023. PMID: 37273217
Expert opinion on the use of cladribine tablets in clinical practice.
Sørensen PS, Centonze D, Giovannoni G, Montalban X, Selchen D, Vermersch P, Wiendl H, Yamout B, Salloukh H, Rieckmann P. Sørensen PS, et al. Among authors: yamout b. Ther Adv Neurol Disord. 2020 Jun 24;13:1756286420935019. doi: 10.1177/1756286420935019. eCollection 2020. Ther Adv Neurol Disord. 2020. PMID: 32636933 Free PMC article. Review.
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.
Rieckmann P, Centonze D, Giovannoni G, Hua LH, Oreja-Guevara C, Selchen D, Sørensen PS, Vermersch P, Wiendl H, Salloukh H, Yamout B. Rieckmann P, et al. Among authors: yamout b. Ther Adv Neurol Disord. 2021 Dec 7;14:17562864211058298. doi: 10.1177/17562864211058298. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34899987 Free PMC article. Review.
Ethical use of off-label disease-modifying therapies for multiple sclerosis.
Laurson-Doube J, Rijke N, Helme A, Baneke P, Banwell B, Viswanathan S, Hemmer B, Yamout B. Laurson-Doube J, et al. Among authors: yamout b. Mult Scler. 2021 Aug;27(9):1403-1410. doi: 10.1177/13524585211030207. Epub 2021 Jul 26. Mult Scler. 2021. PMID: 34304636 Free PMC article.
Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region.
Al Tahan AM, Alsharoqi I, Bohlega SA, Dahdaleh M, Daif A, Deleu D, Esmat K, Giampaolo D, Freedman MS, Gwilt M, Hosny H, Inshasi JS, Aljumah M, Khalifa A, Pakdaman H, Szólics M, Yamout BI, Sahraian MA, Zakaria MF. Al Tahan AM, et al. Int J Neurosci. 2014 Sep;124(9):635-41. doi: 10.3109/00207454.2013.865620. Epub 2013 Dec 18. Int J Neurosci. 2014. PMID: 24228830 Review.
122 results